Furthermore, inhibition of their upstream regulators BCR-ABL1 (in chronic myeloid leukemia cells) and FLT3-ITD (in acute myeloid leukemia cells) plus hydroxyurea produced favorable results. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.